Certolizumab pegol
mab
Verifiedfieldschanged
Watchedfieldschanged
Verifiedrevid460025906
Sourcezu/o
TargetTNF alpha
TradenameCimzia
Medlineplusa608041
DailymedidCertolizumab pegol
Pregnancy auC
Routes of administrationSubcutaneous
Atc prefixL04
Atc suffixAB05
Legal auS4
Legal usRx-only
Legal us comment[1]
Legal euRx-only
Legal eu comment[2]
Elimination half-lifeabout 11 days
ExcretionKidney (PEG only)
Cas number428863-50-7
DrugbankDB08904
Chemspideridnone
UniiUMD07X179E
KeggD03441
Chembl1201831
SynonymsCDP870
C2115
H3252
N556
O673
S16

Certolizumab pegol, sold under the brand name Cimzia, is a biopharmaceutical medication for the treatment of Crohn's disease,[3][4] rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. It is a fragment of a monoclonal antibody specific to tumor necrosis factor alpha (TNF-α) and is manufactured by UCB.[5][6][1]

Certolizumab pegol is a therapeutic alternative on the World Health Organization's List of Essential Medicines.[7]

Medical uses

Crohn's Disease
On April 22, 2008, the U.S. Food and Drug Administration (FDA) approved Cimzia for the treatment of Crohn's disease in people who did not respond sufficiently or adequately to standard therapy.[6][8][9]
Rheumatoid arthritis
On June 26, 2009, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending that the European Commission grant a marketing authorisation for Cimzia for the treatment of rheumatoid arthritis only - the CHMP refused approval for the treatment of Crohn's disease. The marketing authorisation was granted to UCB Pharma SA in October 2009.[2]
Psoriatic arthritis
On September 27, 2013, the U.S. FDA approved Cimzia for the treatment of adult patients with active psoriatic arthritis.[10]

Method of action

Certolizumab pegol is a monoclonal antibody directed against tumor necrosis factor alpha. More precisely, it is a PEGylated Fab' fragment of a humanized TNF inhibitor monoclonal antibody.[11]

Clinical trials

Crohn's disease
Positive results have been demonstrated in two phase III trials (PRECiSE 1 and 2) of certolizumab pegol versus placebo in moderate to severe active Crohn's disease.[3][11][12][13]
Axial spondyloarthritis
In 2013, a phase 3 double blind randomized placebo-controlled study found significantly positive results in patient self-reported questionnaires, with rapid improvement of function and pain reduction, in patients with axial spondyloarthritis.[14]
Rheumatoid arthritis
Certolizumab appears beneficial in those with rheumatoid arthritis.[15]

References

  1. ^ "Cimzia- certolizumab pegol kit Cimzia- certolizumab pegol injection, solution". DailyMed. April 24, 2020. Retrieved July 18, 2020.
  2. ^ "Cimzia EPAR". European Medicines Agency. October 22, 2009. Archived November 9, 2009 at the Wayback Machine. Retrieved November 15, 2009.
  3. ^ Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, Bloomfield R, Schreiber S (July 2007). "Certolizumab pegol for the treatment of Crohn's disease". The New England Journal of Medicine. 357 (3): 228–238. doi:10.1056/NEJMoa067594. PMC 3187683. PMID 17634458
  4. ^ Goel N, Stephens S (2010). "Certolizumab pegol". mAbs. 2 (2): 137–147. doi:10.4161/mabs.2.2.11271. PMC 2840232. PMID 20190560
  5. ^ Kaushik VV, Moots RJ (April 2005). "CDP-870 (certolizumab) in rheumatoid arthritis". Expert Opinion on Biological Therapy. 5 (4): 601–606. doi:10.1517/14712598.5.4.601. PMID 15934837. S2CID 21974683
  6. ^ "Drug Approval Package: Cimzia (Certolizumab Pegol) NDA #125160". U.S. Food and Drug Administration (FDA). December 24, 1999. Archived February 15, 2015 at the Wayback Machine. Retrieved July 18, 2020.
  7. ^ The selection and use of essential medicines, 2025: WHO Model List of Essential Medicines, 24th list. Geneva: World Health Organization. 2025. doi:10.2471/B09474. hdl:10665/382243
  8. ^ "Cimzia Approved in the US for the Treatment of Moderate to Severe Crohn's Disease". UCB press release. Archived February 18, 2012 at the Wayback Machine. Retrieved April 22, 2008.
  9. ^ Waknine Y (May 1, 2008). "FDA Approvals: Patanase, Actonel, Cimzia". Medscape. Retrieved May 1, 2008.
  10. ^ "Cimzia (certolizumab pegol) approved by the U.S. FDA for treatment of adult patients with active psoriatic arthritis". Archived October 1, 2013 at the Wayback Machine. Retrieved October 1, 2013.
  11. ^ Schreiber S, Khaliq-Kareemi M, Lawrance I, Hanauer S, McColm J, Bloomfield R, Sandborn W (2005). "Certolizumab pegol, a humanised anti-TNF pegylated FAb' fragment, is safe and effective in the maintenance of response and remission following induction in active Crohn's disease: a phase 3 study (precise)". Gut. 54 (suppl 7): A82.
  12. ^ Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, McColm JA, Innes A, Schreiber S (2006). "Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn's disease: results from a 26-week, placebo-controlled Phase 3 study (PRECiSE 1)". Gastroenterology. 130 (4): A107.
  13. ^ "New Analysis Shows Cimzia (Certolizumab Pegol) Maintained Remission and Response in Recent Onset Crohn's Disease". UCB. October 23, 2006. Archived March 29, 2020 at the Wayback Machine. Retrieved November 15, 2009.
  14. ^ Sieper J, Tubergen A, Coteur G, Woltering F, Landewe R (May 2013). "PMS50 – Rapid Improvements In Patient-Reported Outcomes With Certolizumab Pegol In Patients With Axial Spondyloarthritis, Including Ankylosing Spondylitis And Non-Radiographic Axial Spondyloarthritis: 24-Week Results Of A Phase 3 Double Blind Randomized Placebo-Controlled Study". Value in Health. 16 (3): A227. doi:10.1016/j.jval.2013.03.1150
  15. ^ Ruiz Garcia V, Burls A, Cabello JB, Vela Casasempere P, Bort-Marti S, Bernal JA (September 2017). "Certolizumab pegol (CDP870) for rheumatoid arthritis in adults". The Cochrane Database of Systematic Reviews. 2017 (9). doi:10.1002/14651858.CD007649.pub4. PMC 6483724. PMID 28884785